A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
ORGANIZATION
Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
Major pharma trade organizations on June 6 welcomed a draft report broadly adopted by a key health ministry expert panel for comprehensive measures to ensure rapid and stable drug supplies, expressing their expectations for concrete steps to follow. In its…
To read the full story
Related Article
ORGANIZATION
- Labor Union Calls for Uniform Hike in Drug Prices, Lawmakers Urge Overhaul
October 29, 2025
- JMA Renews Opposition to Insurance Review for OTC-Like Drugs
October 24, 2025
- MFN Drug Pricing Already Affecting 4 Firms’ R&D Plans in Japan, EFPIA Chief Flags Fallout
October 22, 2025
- JPMA Chief Hails Takaichi’s Election as PM, Calls for Stronger Innovation Ecosystem
October 22, 2025
- Wholesalers to Broaden Lobbying Push to Include Ishin amid Political Shift: Leader
October 17, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…